Patents Examined by Oluwatosin Ogunbiyi
  • Patent number: 10729780
    Abstract: The present invention provides methods for preparation of stable multivalent pneumococcal polysaccharide-protein conjugate vaccine formulations. Instant stable formulations show optimal percent adsorption for each conjugate wherein, aggregation can be prevented by employing i) Individual or separate adsorption for conjugates that otherwise show lower percent adsorption by combined adsorption ii) Histidine-Succinic acid buffer system along with shift in pH from neutral pH to acidic pH iii) a polysaccharide to protein ratio between 0.5 to about 1.4 iv) a six-bladed Rushton type turbine impeller in formulation vessels.
    Type: Grant
    Filed: June 3, 2016
    Date of Patent: August 4, 2020
    Assignee: Serum Institute of India Private Ltd.
    Inventors: Rajeev Mhalasakant Dhere, Hitesh Kumar Malviya, Swapan Kumar Jana, Sambhaji Shankar Pisal, Asha Dinesh Mallya, Sunil Mahor, Manish Maheshkumar Gautam, Chetan Vilas Joshi, Venkata Vamsi Krishna Malepati, Prashant Shivaji Jadhav
  • Patent number: 10722573
    Abstract: Embodiments of the invention are directed to methods of treating, inhibiting or attenuating a microbial infection in an individual who has or is at risk for developing such an infection, comprising the step of administering an effective amount of a StIR composition to the individual.
    Type: Grant
    Filed: November 18, 2016
    Date of Patent: July 28, 2020
    Assignee: THE BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: Burton Dickey, Michael Tuvim, Scott Evans
  • Patent number: 10696974
    Abstract: The invention relates to plasmids capable of expressing a protein targeting immune cells when transformed into a lactic acid bacterial cell, wherein the protein is chosen from the group consisting of murine and human CXCL12 1?; CXCL17 and Ym1. The invention further relates to lactic acid bacteria transformed with a said plasmid, as well as the use of said lactic acid bacteria for wound healing in humans and animals.
    Type: Grant
    Filed: December 23, 2015
    Date of Patent: June 30, 2020
    Assignee: ILYA PHARMA AB
    Inventor: Evelina Vågesjö
  • Patent number: 10682404
    Abstract: The present invention provides antigenic polypeptides expressed during an infection by a pathogenic organism, such as Acinetobacter and compositions comprising these polypeptides. The invention further provides compositions for use in treating, preventing or detecting a bacterial infection, in particular vaccine compositions using the antigenic polypeptides. The invention further provides antibodies directed to said antigenic polypeptides.
    Type: Grant
    Filed: September 25, 2019
    Date of Patent: June 16, 2020
    Inventors: Simon Urwyler, Markus Haake, Michael Rudolf
  • Patent number: 10675347
    Abstract: A method and system for the treatment of honey bees (Apis mellifera), bats, and butterflies protects them from various life threatening conditions, including Colony Collapse Disorder, white nose syndrome, etc. and in particular, provides honey bees, bats and butterflies with the ability to assimilate and degrade pesticides such as neonicotinoids and fipronil.
    Type: Grant
    Filed: January 14, 2019
    Date of Patent: June 9, 2020
    Inventor: Joseph E. Kovarik
  • Patent number: 10653765
    Abstract: The present invention relates to a life attenuated Bordetella pertussis vaccine which is deficient for tracheal cytotoxin (TCT), pertussis toxin (PTX), and dermonecrotic toxin (DNT) for prophylaxis or treatment of an allergen-driven airway pathology.
    Type: Grant
    Filed: August 9, 2019
    Date of Patent: May 19, 2020
    Inventors: Camille Locht, Bernard Mahon, Heather Kavanagh
  • Patent number: 10653630
    Abstract: The presently disclosed subject matter relates to a composition and method of using the composition for oral delivery of a bioactive agent to a subject. More particularly, the presently disclosed subject matter relates to a composition comprising an effective amount of at least one bioacitve agent layered over a substrate and a method of reducing zoonotic infectious disease by administering the composition to a subject. The presently disclosed subject matter further relates to a method of preparing the composition.
    Type: Grant
    Filed: December 21, 2016
    Date of Patent: May 19, 2020
    Assignee: US Biologic, Inc.
    Inventors: Douglas Steven Zatechka, Mason Kauffman, Chris Przybyszewski
  • Patent number: 10639349
    Abstract: The invention features compositions comprising an H3T3A mutant protein. Described herein are methods of inducing cell death in a rapidly dividing cell comprising contacting a rapidly dividing cell with an agent that reduces phosphorylation at threonine 3 of histone 3 (H3T3P), thereby inducing cell cycle arrest followed by cell death. In some cases, the rapidly dividing cell is a tumor cell, e.g., a cancer cell. The agent that reduces phosphorylation of H3T3P comprises an H3T3A mutant protein, e.g., a mutant transgenic protein. Described herein is a kit for arresting cell cycle comprising an agent that reduces phosphorylation H3T3P.
    Type: Grant
    Filed: April 6, 2016
    Date of Patent: May 5, 2020
    Assignee: The Johns Hopkins University
    Inventors: Xin Chen, Jing Xie
  • Patent number: 10632189
    Abstract: Provided herein are compositions, combinations, and methods comprising Canine Respiratory Coronavirus (CRCoV), which are effective in treating or preventing respiratory infections associated secondary pathogens, such as Bordetella bronchiseptica, in animals.
    Type: Grant
    Filed: May 24, 2013
    Date of Patent: April 28, 2020
    Assignee: Zoetis Services LLC
    Inventors: Shelly Lynn Shields, Omar Yousif Abdelmagid
  • Patent number: 10632182
    Abstract: The present invention relates generally to the fields of immunology and vaccine technology. More specifically, the present invention relates to methods for freeze-drying biological preparations, including peptides, antigens, antibodies, and especially, cells. Importantly, the disclosed methods preserve the viability, infectivity and immunogenicity of cells from the Apicomplexa phylum, the Sarcocystidae family, and in particular, cells from the Toxoplasma genus.
    Type: Grant
    Filed: May 13, 2015
    Date of Patent: April 28, 2020
    Inventors: Noel Yves Henri Jean Genin, Jean-Christophe Audonnet, Didier Roy, Edouard Seche, Patrick Gervais, Samira Khaldi-Plassart, Romain Useo, Joelle DeConinck
  • Patent number: 10633643
    Abstract: An engineered payload-delivery system includes a target cell binding unit, covalently bound to a pore forming unit, and a payload portion adapted with a region capable of non-covalently binding to the pore forming unit. The pore forming unit is derived from a particular sub-serotype of Clostridium toxin, while the payload region is derived from a different sub-serotype of Clostridium toxin. The disclosed chimeric protein-based composition is capable of specifically delivering payload to neural cells.
    Type: Grant
    Filed: May 14, 2016
    Date of Patent: April 28, 2020
    Assignee: Board of Regents of the University of Nebraska
    Inventors: Benjamin J. Pavlik, Paul Blum, Kevin Van Cott
  • Patent number: 10627412
    Abstract: The present invention provides an inhibitor of an autoimmune response to a periodontal bacterial enzymatic degradation product of keratin in gingival epithelium in a mammal having a periodontal bacterium in the oral cavity, containing a substance having affinity to the keratin or a degradation product thereof and/or a substance having affinity to an autoantibody to the degradation product, an agent for the prophylaxis and/or treatment of a periodontal disease and/or a complication thereof; a RANKL expression inhibitor containing a substance having affinity to the keratin or a degradation product thereof; and a method of diagnosing a periodontal disease including detecting the keratin or a degradation product thereof and/or an autoantibody thereto.
    Type: Grant
    Filed: March 17, 2011
    Date of Patent: April 21, 2020
    Assignee: KAGOSHIMA UNIVERSITY
    Inventors: Ikuro Maruyama, Teruto Hashiguchi, Salunya Tancharoen, Ko-ichi Kawahara, Kenji Tanaka, Lyang-ja Lee
  • Patent number: 10610552
    Abstract: A nutrient-germinant composition to aid in spore germination and a method for increased spore germination efficiency. The composition comprises L-amino acids, D-glucose and/or D-fructose, a phosphate buffer, an industrial preservative, and may include bacteria spores or they may be separately combined for germination. The method comprises providing a nutrient-germinant composition and bacteria spores, preferably of one or more Bacillus species, and heating to a preferred elevated temperature range of 41° C. to 44° C. for an incubation period of around 2 to 60 minutes. The nutrient-germinant composition is preferably in a concentrated liquid form that is diluted just prior to initiating the germination/incubation method at the point of use. The method may also include dispensing a germinated spore solution to a point-of-use/consumption, such as animal feed, water, or bedding, or a wastewater system or drain.
    Type: Grant
    Filed: April 5, 2017
    Date of Patent: April 7, 2020
    Assignee: NCH Corporation
    Inventors: Gabriel F. K. Everett, Charles Greenwald, Judy Pruitt, Amanda Rosmarin, Jordan Church, Daniel Aberle, George Aboagye
  • Patent number: 10603373
    Abstract: The present invention provides antigenic polypeptides expressed during an infection by a pathogenic organism, such as Acinetobacter and compositions comprising these polypeptides. The invention further provides compositions for use in treating, preventing or detecting a bacterial infection, in particular vaccine compositions using the antigenic polypeptides. The invention further provides antibodies directed to said antigenic polypeptides.
    Type: Grant
    Filed: September 7, 2018
    Date of Patent: March 31, 2020
    Inventors: Simon Urwyler, Markus Haake, Michael Rudolf
  • Patent number: 10603372
    Abstract: The present invention provides antigenic polypeptides expressed during an infection by a pathogenic organism, such as Acinetobacter and compositions comprising these polypeptides. The invention further provides compositions for use in treating, preventing or detecting a bacterial infection, in particular vaccine compositions using the antigenic polypeptides. The invention further provides antibodies directed to said antigenic polypeptides.
    Type: Grant
    Filed: February 13, 2018
    Date of Patent: March 31, 2020
    Inventors: Simon Urwyler, Markus Haake, Michael Rudolf
  • Patent number: 10588897
    Abstract: Described herein are assays for identifying piericidins and piericidin compositions.
    Type: Grant
    Filed: September 24, 2018
    Date of Patent: March 17, 2020
    Assignee: The Regents of the University of California
    Inventors: Victoria Auerbach Stone, Roger G. Linington, Weng Ruh Wong, Miles C. Duncan
  • Patent number: 10585097
    Abstract: Herein is reported a method for determining bacterial endotoxin at low concentrations in a sample of an antibody (that has been produced using bacterial cells) comprising the following steps in the following order: i) adding magnesium ions to the sample, ii) diluting the sample, iii) dialyzing the sample having a pH-value of 5.7-8.0 against an endotoxin-free aqueous solution, and iv) determining bacterial endotoxin in the sample using a bacterial endotoxin test, particularly the limulus amoebocyte lysate assay.
    Type: Grant
    Filed: July 27, 2016
    Date of Patent: March 10, 2020
    Assignees: Forschungszentrum Borstel Leibniz Lungerzentrum, Hoffmann-La Roche Inc.
    Inventors: Christian Alexander, Sven Deutschmann, Pierre Lang, Friedrich Von Wintzingerode, Ulrich Zaehringer
  • Patent number: 10583186
    Abstract: The invention features probiotic bacteria expressing Clostridium difficile SlpA, or fragment thereof, and its use for the treatment or prevention of Clostridium difficile infection and gut colonization.
    Type: Grant
    Filed: January 22, 2016
    Date of Patent: March 10, 2020
    Assignees: ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA, THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS
    Inventors: Gayatri Vedantam, Virinchipuram K. Viswanathan, Michael Mallozzi
  • Patent number: 10583189
    Abstract: The present invention relates to a therapy for treating or preventing several diseases in animals, based on the administration of a highly concentrated avian derived immunoglobulins formulation, obtained from the egg yolk from hens previously hiper-immunized with a vaccine formulation comprising infectious agents or toxins antigens, a light mineral oil and a particulate adjuvant.
    Type: Grant
    Filed: August 22, 2014
    Date of Patent: March 10, 2020
    Assignee: Investigacion Aplicada, S.A. DE C.V.
    Inventors: Eduardo Lucio Decanini, José Andrés Morales Garzon
  • Patent number: 10583185
    Abstract: Compositions and methods are described for inducing an immune response against extra-intestinal pathogenic Escherichia coli (ExPEC) to thereby provide immune protection against diseases associated with ExPEC. In particular, compositions and methods are described for using conjugates of E. coli polysaccharide antigens O25B, O1A, O2, and O6A covalently bound to a detoxified exotoxin A of Pseudomonas aeruginosa (EPA) carrier protein as vaccines for the prevention of invasive ExPEC disease caused by ExPEC serotypes O1A, O2, O6A and O25B.
    Type: Grant
    Filed: August 24, 2016
    Date of Patent: March 10, 2020
    Assignees: GlaxoSmithKline Biological S.A., Janssen Pharmaceuticals, Inc.
    Inventors: Jan Theunis Poolman, Bert Jacquemyn, Darren Robert Abbanat, Patricia Ibarra Yon, Peter Wilhelmus Maria Hermans, Michael Thomas Kowarik, Michael Lukas Wetter, Stefan Jochen Kemmler, Micha Andres Häuptle, Veronica Gambillara Fonck, Manuela Mally